These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25157275)

  • 1. Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.
    Mairinger FD; Walter RF; Theegarten D; Hager T; Vollbrecht C; Christoph DC; Worm K; Ting S; Werner R; Stamatis G; Mairinger T; Baba H; Zarogoulidis K; Huang H; Li Q; Tsakiridis K; Zarogoulidis P; Schmid KW; Wohlschlaeger J
    J Cancer; 2014; 5(8):646-54. PubMed ID: 25157275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence.
    Grøndahl V; Binderup T; Langer SW; Petersen RH; Nielsen K; Kjaer A; Federspiel B; Knigge U
    Lung Cancer; 2019 Jun; 132():141-149. PubMed ID: 31097087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
    Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
    Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.
    Jones MH; Virtanen C; Honjoh D; Miyoshi T; Satoh Y; Okumura S; Nakagawa K; Nomura H; Ishikawa Y
    Lancet; 2004 Mar; 363(9411):775-81. PubMed ID: 15016488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
    Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
    Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
    Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours.
    Zhang Z; Wang M
    Oncol Lett; 2017 Aug; 14(2):1373-1378. PubMed ID: 28789352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
    Schnabel PA; Junker K
    Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
    Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
    Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine neoplasms of the lung: a prognostic spectrum.
    Asamura H; Kameya T; Matsuno Y; Noguchi M; Tada H; Ishikawa Y; Yokose T; Jiang SX; Inoue T; Nakagawa K; Tajima K; Nagai K
    J Clin Oncol; 2006 Jan; 24(1):70-6. PubMed ID: 16382115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in neuroendocrine lung tumors.
    Travis WD
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.
    Yeh YC; Chou TY
    J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.
    Vollbrecht C; Werner R; Walter RF; Christoph DC; Heukamp LC; Peifer M; Hirsch B; Burbat L; Mairinger T; Schmid KW; Wohlschlaeger J; Mairinger FD
    Br J Cancer; 2015 Dec; 113(12):1704-11. PubMed ID: 26645239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States.
    Shah S; Gosain R; Groman A; Gosain R; Dasari A; Halfdanarson TR; Mukherjee S
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33916960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases.
    Travis WD; Linnoila RI; Tsokos MG; Hitchcock CL; Cutler GB; Nieman L; Chrousos G; Pass H; Doppman J
    Am J Surg Pathol; 1991 Jun; 15(6):529-53. PubMed ID: 1709558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular markers help characterize neuroendocrine lung tumors.
    Rusch VW; Klimstra DS; Venkatraman ES
    Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
    Walter RFH; Sydow SR; Berg E; Kollmeier J; Christoph DC; Christoph S; Eberhardt WEE; Mairinger T; Wohlschlaeger J; Schmid KW; Mairinger FD
    Cancer Manag Res; 2019; 11():8711-8720. PubMed ID: 31576173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
    Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
    Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.